11/18/2016 08:30 a.m. - 12:30 p.m.
Capital Markets, IPOs, Private Placements + PIPEs, Banking + Financial Services, Financial Institutions + Financial Services, Equity Offerings, Financial Institutions | Europe, Life Sciences, and Late Stage Investments
Morrison & Foerster LLP Potsdamer Platz 1 13th Floor Berlin, Germany 10785
James R. Tanenbaum and Anna T. Pinedo
Anna T. Pinedo and James R. Tanenbaum
Morrison & Foerster and Raymond James invite you to join us for a discussion on Financing Opportunities for Technology and Life Sciences-Based Companies in Munich and Berlin.
The U.S. capital markets remain an attractive source of capital for emerging companies in the technology and biotech sectors. Late stage (or mezzanine) private placements made principally to U.S. institutional investors have raised in excess of $44.9 billion for privately held companies in 2015. Although the U.S. IPO market has become more selective, there has been continued investor interest in offerings by non-U.S. domiciled issuers. In 2015, 27% of the IPO issuers on a U.S exchange were non-U.S. issuers.
A U.S. securities exchange listing provides a currency for issuers to use in connection with future acquisitions and stock-based compensation awards, and provides enhanced liquidity for existing holders. Finally, as a U.S.-listed issuer, a company will have many more financing choices available to it in the future.
We will discuss:
We look forward to an interesting event and inspiring discussions.
©1996-2017 Morrison & Foerster LLP. All rights reserved.